Related references
Note: Only part of the references are listed.Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations
Federico Martinon-Torres et al.
PATHOGENS AND GLOBAL HEALTH (2022)
Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naive toddlers: A randomised, controlled trial
Markus Knuf et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB
Rafik Bekkat-Berkani et al.
JOURNAL OF INFECTION (2022)
Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review
Anna Deal et al.
LANCET INFECTIOUS DISEASES (2021)
Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
Sara Viksmoen Watle et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States
Lee-Jah Chang et al.
VACCINE (2020)
The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination
Sydel R. Parikh et al.
JOURNAL OF INFECTION (2020)
Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study
Mandeep S. Dhingra et al.
VACCINE (2020)
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naive Children 2-9 Years of Age: A Phase III, Randomized Study
Carmen I. Baccarini et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2020)
Vaccines against Meningococcal Diseases
Mariagrazia Pizza et al.
MICROORGANISMS (2020)
Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs
Myint Tin Tin Htar et al.
BMC PUBLIC HEALTH (2020)
A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines
Jamie Findlow et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis
Bing Wang et al.
VACCINE (2019)
ost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents
Si Si et al.
VACCINE (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Costs of Invasive Meningococcal Disease: A Global Systematic Review
Bing Wang et al.
PHARMACOECONOMICS (2018)
Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data
Caroline L. Trotter et al.
LANCET INFECTIOUS DISEASES (2017)
Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada
Thomas E. Delea et al.
PLOS ONE (2017)
The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines
Stephen I. Pelton
JOURNAL OF ADOLESCENT HEALTH (2016)
Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers
Gianni Bona et al.
VACCINE (2016)
Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015
H. Campbell et al.
EUROSURVEILLANCE (2015)
Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: Systematic review and meta-analysis
Paolo Pellegrino et al.
PHARMACOLOGICAL RESEARCH (2015)
Review of meningococcal vaccines with updates on immunization in adults
Yorgo C. Zahlanie et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age
Scott A. Halperin et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2014)
Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study
Markus Knuf et al.
EUROPEAN JOURNAL OF PEDIATRICS (2013)
Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands
Hiltsje Hepkema et al.
PLOS ONE (2013)
Meningococcal disease: Clinical presentation and sequelae
David Pace et al.
VACCINE (2012)
Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers
Timo Vesikari et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
The Role of Cost-Effectiveness in US Vaccination Policy
Jane J. Kim
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age
Roger Baxter et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2011)
An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children
Markus Knuf et al.
VACCINE (2011)
Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial
Timo Vesikari et al.
VACCINE (2011)
Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America
D. Stamboulian et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2010)
Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age
Scott A. Halperin et al.
VACCINE (2010)
A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
M. Knuf et al.
VACCINE (2010)
Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra
Keith S. Reisinger et al.
CLINICAL AND VACCINE IMMUNOLOGY (2009)
Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents
Lisa A. Jackson et al.
CLINICAL INFECTIOUS DISEASES (2009)
Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease
Dan M. Granoff
VACCINE (2009)
Meningococcal surrogates of protection - serum bactericidal antibody activity
R Borrow et al.
VACCINE (2005)
Share Paper
